BOPI 02 BR / 2025 REPERTOIRE NUMERIQUE 12 Fig. 1 ________________________________________ (11) 21788 Consulter le mémoire (51) A61K 31/519 (2023.01); A61P 43/00 (2023.01); C07D 515/04 (2023.01) (21) 1202300152 - PCT/US2021/053861 (22) 06/10/2021 (30) US n° 63/088, 799 du 07/10/2020 (54) Modulators of cystic fibrosis transmembrane conductance regulator. (72) ARUMUGAM, Vijayalaksmi (US); KRENITSKY, Paul (US); MILLER, Mark Thomas (US); CLEVELAND, Thomas (US); COON, Timothy Richard (US); FRIEMAN, Bryan A. (US); MCCARTNEY, Jason (US); SILINA, Alina (US); ZHOU, Jinglan (US); HADIDA RUAH, Sara Sabina (US); ABELA, Alexander Russell (US); ANDERSON, Corey Don (US); PIERRE, Fabrice (US); ABRAHAM, Sunny (US); CHAU, Jaclyn (US); CLEMENS, Jeremy (US); FANNING, Lev Tyler Dewey (US); VALDEZ, Lino (US); DINH, Andrew (US); DWIGHT, Timothy A. (AE); ISHIHARA, Yoshihiro (US); TRAN, Joe A. (US) et GROOTENHUIS, Peter (deceased) (US) (73) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, BOSTON, Massachusetts 02210 (US) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators. (molécule I) Formula I
RkJQdWJsaXNoZXIy MTM1NDc3MA==